Trial
NCT02106091
Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Affimed GmbH
Collaborators
—
Condition
Relapsed B-Cell Non-Hodgkin Lymphoma
Intervention
AFM11
Why stopped
Non-favorable risk/benefit profile with studied dosing regimen
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-18